About MAX-001
A non-opioid, non-NSAID analgesic for treatment of moderate to severe pain without opioid and NSAID associated side effects.
- MAX-001 is thought to be a centrally-acting agent exerting anti-nociceptive effects via a triple neurotransmitter mechanism of action.
- The active molecule in MAX-001 is indicated for the treatment of pain and has been used extensively as an analgesic outside the US for several decades resulting in a well characterized safety and efficacy profile.
- The utilization of the active molecule in MAX-001 has been significant and still growing:
- 119 million doses OUS.1
- CAGR of 13%.
- The analgesic effects of the active molecule in MAX-001 have been demonstrated when used alone or in combination with other analgesics to produce an equipotent effect often reducing doses and side-effects of the others.
Qualitative Market Research2 indicated:
- High degree of congruence between actual usage of the active molecule in MAX-001 outside the US and projected usage of MAX-001 within the US regardless of physician type:
- Physicians all desire more treatment options to opioids and NSAIDs to treat patients more effectively and safely.
- MAX-001, with its novel MOA, may fill a sizable pain relief void caused by the opioid crisis.
It is ideal as an opioid sparing medication to use before opioids, with hopes to either avoid opioids or minimize their usage. - It would be used as a way to boost pain therapy and avert the need for opioids while minimizing AEs, by adding it to first and second line agents like NSAIDs and acetaminophen.
- It may also be used as a first line agent for moderate pain as a single agent or combined with other analgesics.
- In more severe pain situations like surgery patients, MAX-001 may be initiated with opioids with the hope to titrate down or off the opioids faster.